BACKGROUND Progressive brain atrophy is associated with Alzheimer disease (AD) and other dementias. Regional differences in brain atrophy may reflect clinical features of disease. OBJECTIVE To identify regions of cerebral atrophy that are associated with AD vs other dementias. SETTING University hospital dementia clinic. PARTICIPANTS Eleven patients with AD and 11 with semantic dementia (...

Informative genetic testing is currently available to only a small number of families with a history of early-onset (younger than 60 years of age) Alzheimer disease (AD). For these families, the benefits of genetic testing are limited and are mainly related to the individual’s perception of the psychological advantages of knowing whether or not he or she is predisposed to develop AD. There rema...

BACKGROUND Neuropsychologic testing is often used to infer neuropathologic processes, but clinicopathologic correlations for individual cognitive measures are based on a small number of published studies. OBJECTIVE To examine the usefulness of the age- and education-adjusted Mayo Cognitive Factor Scales (MCFS) obtained at participants' initial assessments for predicting the presence or absenc...

Longitudinal studies on mouse models related to Alzheimer disease (AD) pathology play an important role in the investigation of therapeutic targets help pharmaceutical research development new drugs and attempt early diagnosis that can contribute improving people’s quality life. There are several advantages enriching longitudinal AD with Positron Emission Tomography (PET); among these advantage...

Introduction:Brain imaging with F-18 fluorodeoxyglucose (18F-FDG) positron ‎emission tomography or Tc-99m hexamethylpropyleneamine oxime (‎99mTc-HMPAO) SPECT is widely used for the evaluation of Alzheimer's ‎dementia (AD); we aim to assess superiority of one method over the ‎other. Methods: Twenty four patients with clinical diagnosi...

Alzheimer disease (AD) is a dementing, neurodegenerative disorder that affects approximately 500,000 Canadians and its prevalence is expected to double over the next 30 years. Although several medications may temporarily augment cognitive abilities in AD, there presently exists no proven method to avoid the inevitable clinical deterioration in this devastating condition. The delineation of risk...

Title of Document: OF MICE AND MATH: A SYSTEMS BIOLOGY MODEL FOR ALZHEIMER‟S DISEASE Christina Rose Kyrtsos Doctor of Philosophy 2011 Directed By: Dr. John S. Baras Professor Institute for Systems Research Alzheimer‟s disease (AD) is the most prevalent neurodegenerative disorder in the US, affecting over 1 in 8 people over the age of 65. There are several well-known pathological changes in the ...

The discovery that intact Alzheimer amyloid precursor protein is present in platelet granules, has created a great interest in the biochemistry, physiology and function of platelets of patients with Alzheimer disease (AD). In this study we monitored various biochemical and physiological parameters, such as serotonin and adenine nucleotide levels, membrane fluidity, agonist-mediated release of a...

background and objective: alzheimer’s disease (ad) is a multifactorial disease with debilitating consequences and few therapeutic strategies exist for it. with regard to antioxidant capacity and anti-β-amyloid polymerization potential of ellagic acid, this study was conducted to evaluate the effect of this substance on enhanced acetylcholinesterase reactivity in an experimental model of alzheim...

OBJECTIVE To investigate the cognitive decline in dementia with Lewy bodies (DLBs) and characterize the contribution of Lewy bodies (LBs) to cognitive impairment in the presence of concurrent Alzheimer disease (AD). METHODS Cognitive deficits and rates of progression attributable to DLB and AD neuropathology were investigated in three groups of participants from the longitudinal cohort of the...